Welcome to our dedicated page for ARS Pharms news (Ticker: SPRY), a resource for investors and traders seeking the latest updates and insights on ARS Pharms stock.
Stock Titan’s news page for ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) aggregates company-specific updates for investors and followers of this commercial-stage biopharmaceutical company. ARS Pharma describes its focus as empowering at-risk patients and caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, primarily through its epinephrine nasal spray product, neffy®.
News coverage for SPRY commonly includes announcements about regulatory approvals and geographic expansion of neffy and EURneffy®. Recent press releases highlight approvals for neffy in markets such as Japan and China, as well as launches and approvals in Europe and the U.K. These items provide insight into how ARS Pharma is extending access to its needle-free epinephrine nasal spray through partnerships with companies including ALK, Alfresa Holdings, and Pediatrix Therapeutics.
Investors can also expect commercial and financial updates, such as quarterly financial results, commentary on U.S. commercialization progress, and details on direct-to-consumer campaigns and programs like “Get neffy on Us” and neffyInSchools. These disclosures often describe prescriber adoption, marketing initiatives, and real-world evidence efforts related to neffy’s use in community and clinical settings.
Another key category of SPRY news involves scientific and medical conference activity. ARS Pharma regularly reports on late-breaking oral presentations, poster sessions, and case reports at meetings such as the American College of Allergy, Asthma and Immunology Annual Scientific Meeting, focusing on real-world data, patient experience, dosing rationale, safety, and product stability for intranasal epinephrine.
Additional items may include intellectual property developments, such as decisions from the European Patent Office or the U.S. Patent and Trademark Office, as well as legal and competitive updates like Paragraph IV certification notices regarding potential generic versions of neffy. By following this news feed, readers can monitor how ARS Pharma communicates its regulatory, commercial, scientific, and legal milestones related to neffy and its intranasal epinephrine program.
ARS Pharmaceuticals (Nasdaq: SPRY) announced that California K-12 schools are now eligible for the neffyinSchools program, which provides free needle-free neffy® epinephrine nasal spray for emergency use.
The program, launched in January 2025, now spans 24 states with more than 8,000 participating schools; ARS Pharma has donated nearly 45,000 doses to date. Eligible public and private K-12 schools can request two cartons (four single-use doses) of neffy 1 mg and 2 mg at no cost and may receive replacements after use or expiration.
ARS Pharmaceuticals (Nasdaq: SPRY) announced NMPA approval in China for neffy 2 mg (epinephrine nasal spray) for emergency treatment of Type 1 allergic reactions in adults and children ≥30 kg, marking the first community-use epinephrine product approved in China. ARS licensed commercialization rights to Pediatrix Therapeutics (trade name 优敏速®) and expects availability in spring 2026. ARS will receive a $4M final regulatory milestone, be eligible for up to $80M in sales milestones, and royalties in the low double digits; ARS will manufacture and supply product to Pediatrix at cost of goods. ARS and partners also have approvals/launches in Australia, New Zealand (expected), U.S., and Europe.
ARS Pharmaceuticals (Nasdaq: SPRY) will participate in the Piper Sandler 37th Annual Healthcare Conference in New York, December 2-4, 2025.
Company executives Richard Lowenthal, Co-Founder, President and CEO, and Eric Karas, Chief Commercial Officer, will take part in a fireside chat on Wednesday, December 3 at 2:30 pm ET with Piper Sandler analyst David Amsellem. Management will hold one-on-one investor meetings. A live webcast of the fireside chat will be available on the company website and a replay will be archived for 90 days.
ARS Pharmaceuticals (Nasdaq: SPRY) reported third quarter 2025 results and commercial progress for neffy® (epinephrine nasal spray). Q3 revenue was $32.5M, including $31.3M U.S. net product revenue; net loss was $51.2M (−$0.52/share). Cash, cash equivalents and short-term investments totaled $288.2M as of September 30, 2025, after a $100M draw on a $250M term loan facility; shares outstanding were 98,844,178. Commercial milestones: consumer awareness rose from ~20% to 56%, >18,000 HCPs prescribed neffy (an 86% increase), >6,500 schools enrolled, and real-world data (n=680) showed ~90% effective single-dose treatment rates.
ARS Pharma (Nasdaq: SPRY) launched Get neffy on Us on November 4, 2025, an integrated commercial program to expand access to neffy (epinephrine nasal spray).
Key features: a free virtual prescriber visit taking 5–10 minutes, potential $0 co-pay for eligible commercially insured patients, and delivery to a pharmacy or home within 3–5 days. The company cites ~40 million people with severe allergies and survey interest of >70% in virtual prescribing. The program complements neffyInSchools, which has provided neffy to >6,600 schools across >20 states. More information is available at www.getneffy.com or 1-877-MY-NEFFY.
ARS Pharma (Nasdaq: SPRY) will present one late-breaking oral and six poster presentations featuring real-world data on neffy® (epinephrine nasal spray) at the 2025 ACAAI Annual Scientific Meeting in Orlando, Nov 6–10, 2025.
The late-breaking oral presentation, “Real World Data on the Effectiveness of Epinephrine Nasal Spray in Clinical Practice – Update,” is scheduled for Nov 8, 2025 at 5:23 PM ET. Six poster sessions and five clinician case reports will report real-world use, safety, and administration topics. ARS will host onsite activities and exhibit at booth #400.
ARS Pharmaceuticals (Nasdaq: SPRY) will host a conference call and webcast on Monday, November 10, 2025 at 5:30 a.m. PT / 8:30 a.m. ET to discuss third quarter 2025 financial results and business highlights. Dial-in details are available by registering for the event.
Investors can access the live webcast and slides on the company’s Investors & Media > Events & Presentations page. A replay of the webcast will be available for 30 days after the event.
ARS Pharma (Nasdaq: SPRY) will present one late-breaking oral and six poster presentations on neffy® (epinephrine nasal spray) at the ACAAI Annual Scientific Meeting, Nov 6-10, 2025 in Orlando.
Presentations include a late-breaking oral update reporting that about 9 of 10 patients with anaphylaxis were effectively treated with a single dose of neffy, five case reports of in-clinic use, and posters on patient experience, dosing technique, safety, stability, and second-dose rationale.
Attendees can visit booth #400 and multiple onsite sessions for more details.
ARS Pharmaceuticals (NASDAQ: SPRY) announced the European Patent Office Opposition Division upheld all claims of EP 3678649, a patent covering nasal spray epinephrine formulations including alkyl-glycoside excipients such as Intravail®. The patent is validated in over 30 European countries and ARS states its global intellectual property for neffy provides coverage through at least 2039. Earlier in 2025 the USPTO also upheld key claims of U.S. Patent No. 10,682,414 after an IPR challenge and appeal, giving ARS two different patents with differing claim scope sustained in separate jurisdictions.
Company commentary framed the rulings as reinforcing the strength of its worldwide patent estate that covers intranasal epinephrine.
ARS Pharmaceuticals (NASDAQ: SPRY) has secured a substantial $250 million senior secured term loan facility from RA Capital Management and OMERS Life Sciences. The company has initially borrowed $100 million to accelerate the commercialization of neffy®, their needle-free epinephrine treatment for allergic reactions.
The loan facility includes favorable terms with an interest rate of SOFR plus 5.5% and interest-only payments until September 2030. The company has access to additional tranches: $25 million available within 6-12 months, another $25 million subject to achieving $100 million in U.S. revenue, and an uncommitted $100 million incremental term loan.
Market response to neffy® has been strong, with 93% of patients surveyed being "very likely to consider" the treatment and the prescriber base nearly doubling in four months. The company expects the funding to support operations through cash-flow breakeven while targeting the $2 billion annual U.S. epinephrine market.
FAQ
What is the current stock price of ARS Pharms (SPRY)?
What is the market cap of ARS Pharms (SPRY)?
